Removab
catumaxomab
Table of contents
Overview
The marketing authorisation for Removab has been withdrawn at the request of the marketing authorisation holder.
Authorisation details
| Product details | |
|---|---|
| Name |
Removab
|
| Agency product number |
EMEA/H/C/000972
|
| Active substance |
Catumaxomab
|
| International non-proprietary name (INN) or common name |
catumaxomab
|
| Therapeutic area (MeSH) |
|
| Anatomical therapeutic chemical (ATC) code |
L01XC09
|
| Publication details | |
|---|---|
| Marketing-authorisation holder |
Neovii Biotech GmbH
|
| Revision |
5
|
| Date of issue of marketing authorisation valid throughout the European Union |
20/04/2009
|
| Contact address |
Am Haag 6-7
82166 Graefelfing Germany |
Product information
02/06/2017 Removab - EMEA/H/C/000972 - IAIN/0020
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Pharmacotherapeutic group
Other antineoplastic agents
Therapeutic indication
Removab is indicated for the intraperitoneal treatment of malignant ascites in patients with EpCAM-positive carcinomas where standard therapy is not available or no longer feasible.